Kessler Investment Group LLC bought a new position in shares of AbbVie Inc. (NYSE:ABBV) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 7,651 shares of the company’s stock, valued at approximately $555,000.

Other institutional investors have also made changes to their positions in the company. First Command Financial Services Inc. increased its position in shares of AbbVie by 6.8% in the first quarter. First Command Financial Services Inc. now owns 1,565 shares of the company’s stock worth $102,000 after buying an additional 99 shares in the last quarter. Acropolis Investment Management LLC acquired a new position in shares of AbbVie during the second quarter worth $106,000. Franklin Parlapiano Turner & Welch LLC acquired a new position in shares of AbbVie during the first quarter worth $108,000. Patriot Financial Group Insurance Agency LLC acquired a new position in shares of AbbVie during the fourth quarter worth $137,000. Finally, Atwood & Palmer Inc. increased its position in shares of AbbVie by 1,333.3% in the first quarter. Atwood & Palmer Inc. now owns 2,150 shares of the company’s stock worth $140,000 after buying an additional 2,000 shares in the last quarter. 67.89% of the stock is owned by institutional investors and hedge funds.

AbbVie Inc. (NYSE ABBV) traded down 1.14% during midday trading on Thursday, reaching $71.20. 1,647,783 shares of the company’s stock were exchanged. The stock’s 50-day moving average is $72.15 and its 200-day moving average is $66.67. The stock has a market capitalization of $113.50 billion, a price-to-earnings ratio of 17.51 and a beta of 1.50. AbbVie Inc. has a 12-month low of $55.06 and a 12-month high of $75.04. AbbVie also was the target of some unusual options trading activity on Monday. Stock investors purchased 278 put options on the company. This represents an increase of approximately 121% compared to the average volume of 126 put options.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, July 28th. The company reported $1.42 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.40 by $0.02. AbbVie had a net margin of 24.77% and a return on equity of 150.27%. The business had revenue of $6.94 billion for the quarter, compared to analyst estimates of $6.93 billion. During the same quarter in the prior year, the business posted $1.26 EPS. AbbVie’s revenue for the quarter was up 7.6% compared to the same quarter last year. On average, equities analysts forecast that AbbVie Inc. will post $5.52 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, August 15th. Shareholders of record on Friday, July 14th will be paid a dividend of $0.64 per share. The ex-dividend date of this dividend is Wednesday, July 12th. This represents a $2.56 dividend on an annualized basis and a yield of 3.55%. AbbVie’s payout ratio is 62.90%.

ILLEGAL ACTIVITY WARNING: “Kessler Investment Group LLC Buys Shares of 7,651 AbbVie Inc. (ABBV)” was published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/10/kessler-investment-group-llc-buys-shares-of-7651-abbvie-inc-abbv.html.

A number of equities analysts have weighed in on ABBV shares. Vetr downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating and set a $71.84 target price for the company. in a research note on Monday, May 15th. Jefferies Group LLC reissued a “buy” rating on shares of AbbVie in a research report on Friday, May 26th. Societe Generale raised shares of AbbVie from a “hold” rating to a “buy” rating in a research report on Thursday, June 22nd. BidaskClub downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $85.00 price target on shares of AbbVie in a research report on Thursday, August 3rd. Nine research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. AbbVie currently has a consensus rating of “Buy” and an average price target of $74.66.

In other AbbVie news, Chairman Richard A. Gonzalez sold 193,131 shares of the company’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $71.00, for a total transaction of $13,712,301.00. Following the transaction, the chairman now owns 469,623 shares in the company, valued at approximately $33,343,233. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO William J. Chase sold 38,300 shares of the company’s stock in a transaction that occurred on Thursday, May 18th. The shares were sold at an average price of $65.35, for a total transaction of $2,502,905.00. Following the transaction, the chief financial officer now owns 209,043 shares in the company, valued at approximately $13,660,960.05. The disclosure for this sale can be found here. Insiders have sold a total of 600,026 shares of company stock worth $41,852,724 in the last 90 days. 0.23% of the stock is currently owned by company insiders.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.